Julian Blagg
![Julian Blagg Julian Blagg](https://ddr-inhibitors-summit.com/wp-content/uploads/sites/164/2023/09/Julian-Blagg-150x150.jpg)
Company: NeoPhore
Job title: EVP Drug Discovery
Seminars:
NP1867: A Chemical Probe for Exploring the Role of DNA Mismatch Repair in Human Disease 11:30 am
• MMR-deficient (MMR-d) tumors are eligible for immune checkpoint therapy, irrespective of tumors type, providing substantial clinical benefit; however, not all MMR-d patients respond to CPI therapy and correlation of tumors mutational burden with clinical outcome is controversial • Small molecule NP1867 potently and selectively binds to the MutLa heterodimer component PMS2 enabling acute and…Read more
day: Day Two Track A